NCT06059222View on ClinicalTrials.gov

The Optimised Use of Romozosumab Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Osteoporosis
Interventions
DRUG

Romosozumab

Romosozumab 210 mg/2.34 ml from baseline to month 11

DRUG

Zoledronate

5 mg/100 ml at month 12

DRUG

Romosozumab

210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23

DRUG

Zoledronate

5 mg/100 ml at month 6

DRUG

Romosozumab

210 mg/2.34 ml from baseline to month 5

DRUG

Zoledronate

5 mg/100 ml at month 5 and month 18

Trial Locations (1)

8000

RECRUITING

Department of Endrocinology and Internal Medicine, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER